3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Neoplasm Metastasis
1
Liver Cirrhosis
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Gemcitabine
685
130-nm albumin-bound paclitaxel
199
Fluorouracil
190
Oxaliplatin
177
Albumin-Bound Paclitaxel
154
Capecitabine
137
Leucovorin
133
Irinotecan
114
Radiotherapy
96
Taxes
85
pembrolizumab
81
Cisplatin
73
Erlotinib Hydrochloride
70
Radiosurgery
69
Nivolumab
56
Drug Therapy
56
Bevacizumab
54
Magnetic Resonance Spectroscopy
51
Cyclophosphamide
50
folfirinox
45
Specimen Handling
43
Docetaxel
42
Cetuximab
40
Biopsy
39
irinotecan sucrosofate
38
S 1 (combination)
36
Pancreaticoduodenectomy
35
Blood Specimen Collection
34
Surgical Procedures, Operative
31
Paclitaxel
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Mebendazole
×
Gastrointestinal
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn